Orange County Convention Center

Are Checkpoint Inhibitors effective in Prostate Cancer?

Many readers will be aware that the ASCO Genitourinary Symposium (ASCO GU) Symposium in Orlando took place this past weekend. In recent years the treatment of advanced prostate cancer has been dramatically improved thanks the approval of new treatments such as abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in the pre and post chemotherapy setting. So […]

Continue Reading
Dr Julianne Smith Cellectis

2015 is the year of Gene Editing

Last year we (and many others) declared 2014 to be the year of immuno-oncology, and while this will continue to remain a hot area for drug development, we predict 2015 will be the year of gene editing. Many people in industry are now aware that you can modify T cells by the introduction of a […]

Continue Reading
ASH 2014 GvHD Plenary Wei Li

Top 5 Highlights of ASH 2014

At the annual meeting of the recent American Society of Hematology (ASH) in San Francisco there was a wealth of new information and data for consumption. At the risk of ignoring a lot compelling clinical data, Daedalus would like offer up five highlights from the meeting. Whether these are “top” is entirely a subjective and […]

Continue Reading
National Harbor MD

What’s Exciting in Cancer Immunotherapy?

A record attendance of over 1500 attendees went to the annual meeting of the Society for Immunotherapy of Cancer (SITC) last weekend at National Harbor in Maryland to hear about the latest developments in cancer immunotherapy. Cancer immunotherapy is about harnessing the body’s immune system to fight cancer. It is the hottest area in cancer […]

Continue Reading
Genentech PDL1 Video

The Promise of PD1 PDL1 Immunotherapy

The immune system is used to dealing with foreign invaders such as bacteria and pathogens. One of the challenges it faces with cancer is that tumor cells are basically a proliferation of human (self) cells gone awry. The result is it doesn’t recognize them as foreign very well because the mutations and aberrations are in […]

Continue Reading
Miami Beach Lifeguard Tower

Immuno-Oncology drives Pharma Licensing Strategy

Cancer immunotherapy, the ability to harness the body’s own immune system to fight cancer, is showing so much promise that it is driving Pharma corporate strategy. If you don’t have an immuno-oncology pipeline, including a checkpoint inhibitor in development, you may need to go out and find one, that’s the message from this week’s Pharma […]

Continue Reading
Autumn Leaves

Fall 2014 Cancer Conferences to Watch Out for

The leaves are turning and the weather is getting cooler in many parts of the country, so what are some of the cancer conferences to watch out for before the year end? On Biotech Strategy Blog we’ll be writing about four major medical and scientific meetings including SITC 2014 in Maryland, EORTC-NCI-AACR Molecular Targets in […]

Continue Reading
ESMO 2014 Congress - Madrid, Spain

ESMO 2014 Conference Coverage

The ESMO 2014 Congress takes place in Madrid at the end of September (Sept 26 -30) and we are already planning our conference coverage. Sadly, the ESMO and ECCO annual meetings have moved in a negative direction with this year’s meeting excluding nurses, patient advocates and media from the exhibit hall and industry satellite symposia, […]

Continue Reading
Greenwich London

Do you have a fast to market oncology new products strategy?

Pharma marketing strategy is a key part of every consulting project we do, whether it be a landscape report, thought leader market research or identifying target opportunities for oncology and hematology new products. We are constantly on the look out for fast-to-market strategies in market segments with high unmet medical need where emerging science and […]

Continue Reading
Cellectis CSO Phillippe Duchateau and CEO André Choulika

Who will win CAR-T cell immunotherapy race to market?

Chimeric Antigen Receptor T cell immunotherapy (known as CAR-T or more colloquially as CART)  has been in the news recently. Novartis/UPenn announced they received Breakthrough Therapy Designation (BTD) from the US Food & Drug Administration (FDA) for their CTL019 product in relapsed/refractory acute lymphocytic leukemia (ALL). Dr Stephen Grupp from The Children’s Hospital of Philadelphia […]

Continue Reading
error: Content is protected !!